Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Data on late-stage CagriSema trial expected by end of 2024
Novo still confident on 25% weight loss potential -Lange
Data a 'must win' for Novo obesity-driven investments-analysts
Adds quotes, details, from paragraph 4
By Maggie Fick
LONDON, Nov 6 (Reuters) -Novo Nordisk NOVOb.CO said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.
Martin Holst Lange, Novo Nordisk's head of development, made the comments to Reuters after the company released better-than-expected third-quarter results.
The Danish drugmaker is due to release data from a late-stage trial of CagriSema, a two-drug combination obesity treatment that, like its popular obesity drug Wegovy, is injected, by the end of 2024.
CagriSema targets the same gut hormone as Wegovy does, but also targets a pancreas hormone called amylin.
Novo Nordisk has previously said that CagriSema has a potential of up to 25% weight loss, compared with the 15% weight loss of Wegovy.
Lange said on Wednesday the company still expects the data from its Phase 3 trial to reflect this higher weight loss.
"No change in our confidence level," he said.
Analysts view this data as "a must-win" for Novo's obesity-driven investment case, given the hot competition among pharma companies to deliver higher weight loss than Wegovy and Zepbound, the rival obesity injection that U.S. company Eli Lilly LLY.N launched last year.
Novo's share price could go up to 20% higher or lower depending on it, predict ABG Sundal Collier analysts.
Lange said that Novo needed to collect more data on the psychiatric side effects of another experimental obesity treatment, monlunabant, in a Phase 2b trial before it could progress to a Phase 3 or late-stage trial.
The company's shares fell nearly 5% in September after results from a Phase 2a trial of monlunabant, a pill, came in below market expectations. Novo acquired the drug last year as part of its $1 billion purchase of Canadian biotech firm Inversago Pharmaceuticals.
Novo had already planned to conduct a Phase 2b trial even before it got the data from the latest trial, Lange said, but the Phase 2a trial did reveal new psychiatric side effects and suggests that perhaps excessively high dose strengths were tested. The new trial will involve a lower-dose strength, he said.
Monlunabant is a cannabinoid or CB1 receptor blocker. Although it has a similar effect as the GLP-1 drugs already on the market, it has a different mechanism of action.
Reporting by Maggie Fick; Editing by Jan Harvey and Bernadette Baum
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
